Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The study is designed as a Phase III, multi-center trial of tandem autologous transplants
versus the strategy of autologous followed by Human Leukocyte Antigen (HLA)-matched sibling
non-myeloablative allogeneic transplant. Study subjects will be biologically assigned to the
appropriate arm depending on the availability of an HLA-matched sibling. There is a nested
randomized phase III trial of observation versus maintenance therapy following the second
autologous transplant for patients on the tandem autologous transplant arm.
Phase:
Phase 3
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Collaborators:
Blood and Marrow Transplant Clinical Trials Network National Cancer Institute (NCI) National Marrow Donor Program